FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

CGMP Deviations at Zhejiang Tianyu Pharmaceutical

FDA warns Chinas Zhejiang Tianyu Pharmaceutical Co. about CGMP deviations in the production of active pharmaceutical ingredients.

latest-news-card-1
Federal Register

Tissues Office Renamed Office of Therapeutic Products

Federal Register notice: CBERs Office of Tissues and Advanced Therapies has modified its organizational structures to redesignate it a super office t...

latest-news-card-1
Human Drugs

Value in Leveraging Clinical Pharmacology Principles

CDER Office of Clinical Pharmacology researchers outline the value of leveraging clinical pharmacology principles during drug development and evaluati...

latest-news-card-1
Human Drugs

Generic Drug Safety Labeling Legislation

Rep. A Donald McEachin introduces legislation to allow generic drug manufacturers to independently add safety-related information to product labels.

latest-news-card-1
Human Drugs

Pediatric Extrapolation is Expanding: Study

FDA researchers say the use of pediatric extrapolation since 2015 has expanded and been refined.

latest-news-card-1
FDA General

Clean User Fee Bill Added to Continuing Resolution

House and Senate negotiators agree to terms to reauthorize the agencys user fee programs under a clean absent any policy/program riders measure that...

latest-news-card-1
Human Drugs

Warning Issued to German OTC Drug Maker Over GMPs

FDA sends a Warning Letter to German over-the-counter drug manufacturer System Kosmetik Produktionsgesellschaft fur kosmetische after inspecting the f...

latest-news-card-1
Federal Register

Two Proposed Rules Modify Certain IRB Oversight

Federal Register proposed rules: FDA issues two proposed rules that modify certain research requirements regarding approval/oversight by institutional...

latest-news-card-1
Human Drugs

Biogen Pays $900 Million in Whistleblower Suit

Biogen pays $900 million to resolve allegations that it violated the False Claims Act by causing the submission of false claims to Medicare and Medica...

latest-news-card-1
FDA General

Comments on Remote Assessment Guidance

Stakeholders make recommendations they say would improve an FDA draft guidance on remote regulatory assessments.